fda compounding semaglutide enforcement 2025 news What Patients Need to Know About the GLP-1 Policy Changes FDA sets tirzepatide compounding deadlines

The FDA approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease who are also overweight in March 2024, which opened the door for Medicare coverage in that specific population

This is why some clinicians, including Paloma health care providers who prescribe GLP-1 drugs, monitor thyroid function more closely after initiating a GLP-1

Anyone who has used an unlicensed product labelled as retatrutide should seek medical advice if side effects are severe, persistent or worsening

Unfortunately, both carrying excess weight and using GLP-1 medications for weight loss carry a stigma

How might my genetic predispositions affect berberine and GLP-1 combination therapy

GIP also stimulates bone formation and inhibits bone resorption [38], but we dont have any clinical evidence to date of an effect on bone preservation with a GLP- 1/GIP dual agonist for weight loss